Targeting IL-13 with tralokinumab normalizes type 2 inflammation in atopic dermatitis both early and at 2 years.
Guttman-Yassky E, Kabashima K, Staumont-Salle D, Nahm WK, Pauser S, Da Rosa JC, Martel BC, Madsen DE, Røpke M, Arlert P, Steffensen L, Blauvelt A, Reich K.
Guttman-Yassky E, et al. Among authors: madsen de.
Allergy. 2024 Apr 2. doi: 10.1111/all.16108. Online ahead of print.
Allergy. 2024.
PMID: 38563683